AXSM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AXSM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-08), Axsome Therapeutics's current share price is $73.90. Axsome Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $4.48. Axsome Therapeutics's Cyclically Adjusted PS Ratio for today is 16.50.
The historical rank and industry rank for Axsome Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Axsome Therapeutics's highest Cyclically Adjusted PS Ratio was 23.40. The lowest was 15.16. And the median was 18.25.
AXSM's Cyclically Adjusted PS Ratio is ranked worse thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Axsome Therapeutics's adjusted revenue per share data for the three months ended in Mar. 2024 was $1.582. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $4.48 for the trailing ten years ended in Mar. 2024.
The historical data trend for Axsome Therapeutics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Axsome Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | - | - | - | 19.22 | 17.81 |
For the Biotechnology subindustry, Axsome Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Axsome Therapeutics's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Axsome Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 73.90 | / | 4.48 | |
= | 16.50 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Axsome Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Axsome Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 1.582 | / | 131.7762 | * | 131.7762 | |
= | 1.582 |
Current CPI (Mar. 2024) = 131.7762.
Axsome Therapeutics Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201406 | 0.000 | 100.560 | 0.000 |
201409 | 0.000 | 100.428 | 0.000 |
201412 | 0.000 | 99.070 | 0.000 |
201503 | 0.000 | 99.621 | 0.000 |
201506 | 0.000 | 100.684 | 0.000 |
201509 | 0.000 | 100.392 | 0.000 |
201512 | 0.000 | 99.792 | 0.000 |
201603 | 0.000 | 100.470 | 0.000 |
201606 | 0.000 | 101.688 | 0.000 |
201609 | 0.000 | 101.861 | 0.000 |
201612 | 0.000 | 101.863 | 0.000 |
201703 | 0.000 | 102.862 | 0.000 |
201706 | 0.000 | 103.349 | 0.000 |
201709 | 0.000 | 104.136 | 0.000 |
201712 | 0.000 | 104.011 | 0.000 |
201803 | 0.000 | 105.290 | 0.000 |
201806 | 0.000 | 106.317 | 0.000 |
201809 | 0.000 | 106.507 | 0.000 |
201812 | 0.000 | 105.998 | 0.000 |
201903 | 0.000 | 107.251 | 0.000 |
201906 | 0.000 | 108.070 | 0.000 |
201909 | 0.000 | 108.329 | 0.000 |
201912 | 0.000 | 108.420 | 0.000 |
202003 | 0.000 | 108.902 | 0.000 |
202006 | 0.000 | 108.767 | 0.000 |
202009 | 0.000 | 109.815 | 0.000 |
202012 | 0.000 | 109.897 | 0.000 |
202103 | 0.000 | 111.754 | 0.000 |
202106 | 0.000 | 114.631 | 0.000 |
202109 | 0.000 | 115.734 | 0.000 |
202112 | 0.000 | 117.630 | 0.000 |
202203 | 0.000 | 121.301 | 0.000 |
202206 | 0.226 | 125.017 | 0.238 |
202209 | 0.404 | 125.227 | 0.425 |
202212 | 0.561 | 125.222 | 0.590 |
202303 | 2.173 | 127.348 | 2.249 |
202306 | 1.069 | 128.729 | 1.094 |
202309 | 1.227 | 129.860 | 1.245 |
202312 | 1.511 | 129.419 | 1.539 |
202403 | 1.582 | 131.776 | 1.582 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Axsome Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Susan Mahony | director | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Mark Coleman | director | 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004 |
Hunter R. Murdock | officer: General Counsel | 22 CORTLAND STREET, 16TH FLOOR, NEW YORK NY 10007 |
Roger Jeffs | director | |
Nick Pizzie | officer: Chief Financial Officer | 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004 |
Mark E Saad | director | C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
Herriot Tabuteau | director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER | |
Mark L. Jacobson | officer: Chief Operating Officer | 200 BROADWAY, 3RD FLOOR, NEW YORK NY 10038 |
David C Marek | officer: Chief Commercial Officer | C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011 |
John Golubieski | officer: Chief Financial Officer | C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862 |
Myrtle S Potter | director | 10 FINDERNE AVE, BRIDGEWATER NJ 08807 |
Randall Kaye | officer: Chief Medical Officer | 11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121 |
Ames Constance | officer: Vice President, Finance | 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004 |
Antecip Capital Llc | 10 percent owner | 630 5TH AVENUE, SUITE 2074, NEW YORK NY 10111 |
From GuruFocus
By Marketwired • 09-21-2023
By Marketwired • 10-02-2023
By Marketwired • 07-12-2023
By Marketwired • 09-05-2023
By PRNewswire PRNewswire • 05-08-2023
By GuruFocus Research • 11-06-2023
By GlobeNewswire • 06-28-2023
By PRNewswire PRNewswire • 02-27-2023
By Marketwired • 10-10-2023
By sperokesalga sperokesalga • 03-01-2023